STK10 is a serine/threonine kinase of the Ste20 family with diverse roles in immune and vascular biology. Its primary function involves regulating lymphocyte migration through phosphorylation of ERM proteins such as moesin 1, though expression extends beyond lymphoid tissues 1. Recently, STK10 was identified as a critical regulator of platelet function, where it phosphorylates integrin-linked kinase (ILK) at Ser343 to promote platelet activation, aggregation, and arterial thrombosis 2. STK10 activation also mediates thromboinflammation and neutrophil extracellular trap formation 2. Disease relevance spans multiple conditions. STK10 polymorphisms associate with aspirin-intolerant asthma susceptibility, potentially through tissue-specific codon usage affecting airway epithelium expression 3. In cancer, STK10 is overexpressed in acute myeloid leukemia with poor prognostic significance and immune checkpoint associations 4, and represents a potential therapeutic target in uveal melanoma through Gαq/11 signaling regulation 5. Novel pathogenic STK10 mutations impair ribosome biogenesis and activate p53 signaling, causing acquired pure red cell aplasia 6. Altered STK10 kinase activity also correlates with abdominal aortic aneurysm pathophysiology affecting vascular smooth muscle cells 7. These findings establish STK10 as a multi-functional kinase with therapeutic potential across thrombotic, inflammatory, and neoplastic diseases.